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2 
SUMMARY 28 
The drug isoniazid (INH) is a key component of global tuberculosis (TB) control 29 
programmes. It is estimated, however, that 16.1% of TB disease cases in former Soviet 30 
Union countries and 7.5% of cases outside of those settings have non-multidrug resistant 31 
(MDR) INH resistance. Resistance has been linked to poorer treatment outcomes, post-32 
treatment relapse and death, at least for specific sites of disease. Multiple genetic loci are 33 
associated with phenotypic resistance, but the relationship between genotype and 34 
phenotype is complex. This restricts the use of rapid sequencing techniques as part of the 35 
diagnostic process to determine the most appropriate treatment regimens for patients. The 36 
burden of resistance also influences the usefulness of INH preventative therapy. Despite 37 
seven decades of the use of INH our knowledge in key areas- such as the epidemiology of 38 
resistant strains, their clinical consequences, whether tailored treatment regimens are 39 
required, and the role of INH resistance in fuelling the MDR-TB epidemic- is limited. The 40 
importance of non-MDR INH resistance needs to be re-evaluated both globally and by 41 
national TB control programmes.  42 
  43 
3 
INTRODUCTION 44 
In 2013 the Director of the World Health Organization’s (WHO) Global Tuberculosis (TB) 45 
Programme described drug resistant TB as a ‘ticking time bomb’. A need for ‘visionary 46 
political leadership’ was identified.1 Research and public health action in this area has been 47 
dominated by multidrug resistant (MDR; resistance to both rifampicin (RMP) and isoniazid 48 
(INH)) and extensively drug resistant (XDR; MDR plus resistance to a fluoroquinolone and 49 
one or more of three second-line injectables) TB. 50 
 51 
INH, first synthesised in 1912 in Prague,2 is an effective first-line drug for the treatment of 52 
active TB disease.3 A prodrug, INH is activated by the catalase-peroxidase KatG of 53 
Mycobacterium tuberculosis. Following this, it binds InhA, an enoyl-acyl carrier protein 54 
reductase and so blocks fatty (mycolic) acid synthesis, a key component of the bacterial cell 55 
wall. In rapidly dividing bacteria INH is bactericidal, in slower dividing bacteria bacteriostatic. 56 
The drug is thought to provide a high initial kill at the start of active TB treatment, after which 57 
RMP largely takes over in terms of bactericidal activity and RMP and pyrazinamide (PZA) 58 
act as sterilising drugs.4 From its earliest use as monotherapy for TB disease in the 1950s, 59 
rapid and frequent development of resistance to INH was reported. Such observations 60 
regarding INH and other drugs emphasised the need for combination regimens. INH, 61 
streptomycin (STM) and p-aminosalicylic acid thus became the standard regimen for many 62 
years before the development of the current short course of two months of INH, RMP, PZA 63 
and ethambutol (EMB), followed by four months of INH and RMP.4-6 The 1950s also saw the 64 
first studies of INH as a treatment for latent TB infections (LTBI),7 for which it is now a 65 
standard mono- or combination therapy.8;9 66 
 67 
Resistance to INH has been associated with death in TB meningitis patients, where its role 68 
in treatment is even more crucial as the only bactericidal agent to easily traverse the blood-69 
brain barrier.10 Additionally, a systematic review and meta-regression of trial data has 70 
indicated that initial INH resistance increases the incidence rates of treatment failure and 71 
relapse.11 Given its relatively cheap price and low rates of adverse events,3 it is beneficial to 72 
both health services and patients to be able to use INH. It is thus important to control the 73 
spread of primary INH resistance and prevent the acquisition of secondary resistance. 74 
 75 
In this paper, we pose ourselves- and our audience- a single question: is non-MDR INH 76 
resistance of concern? Our answer depends upon a host of considerations- the burden of 77 
INH resistance globally and regionally, the role of different resistance-causing mutations, the 78 
extent to which resistance hinders treatment of active disease, whether tailored treatment 79 
regimens are required, the relationship between INH resistance and MDR- which we 80 
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describe in the following sections. We conclude with how resistance can be prevented and 81 
controlled, our perspectives on the implications of neglecting non-MDR INH resistance, and 82 
the gaps and opportunities for public health.  83 
 84 
GLOBAL BURDEN OF INH RESISTANCE 85 
In 2011, Jenkins et al. produced the first analysis of global INH resistance data reported to 86 
the WHO.12 They found that, from 1994-2009, 131 unique settings (including countries and 87 
sub-national regions) submitted such data at least once. This covered 56% of the world’s 88 
population, meaning that for nearly half of the global population data were not reported at 89 
local or national levels (a key knowledge gap- see Table 1). Of the submitted nationwide 90 
data, the former Soviet Union countries reported the highest percentages of TB cases with 91 
INH resistance: 44.9% had some form of INH resistance (including mono-resistance and 92 
MDR-TB) and 16.1% had non-MDR INH resistance without concurrent RMP resistance 93 
(Figure 1). Across the rest of the world, excluding the former Soviet Union countries, 13.9% 94 
of TB cases had some form of INH resistance (including mono-resistance and MDR-TB) and 95 
7.5% INH resistance without RMP resistance. Between 1994 and 2013, the WHO estimated 96 
that 9.5% of global TB cases had INH resistance without RMP resistance.13 The percentage 97 
of paediatric TB disease with INH resistance reflects the percentage observed among new 98 
adult cases.14 Around 12% of paediatric TB cases globally are estimated to have some form 99 
of INH resistance, amounting to 120,000 new child cases annually. Additionally, Dodd et al. 100 
have estimated that there are 166,000 new INH (without RMP) resistant infections in children 101 
per year.15 As there are specific recommendations for the use of LTBI regimens, including 102 
INH preventative therapy, in young children, such estimates have implications for the 103 
effectiveness of these regimens.9  104 
 105 
Time trend data are important to identify changes in the prevalence of INH resistance (Table 106 
1). Jenkins et al. found that only 51 of the 131 settings above reported three or more 107 
temporal data points and both upward and downward trends were observed, with no clear 108 
global pattern.12 Given the relevance of INH resistance for people living with HIV (since they 109 
are targeted for INH preventative therapy),16 the authors separately examined countries with 110 
estimated adult HIV seroprevalences of at least 2%. In those countries, 7.3% of cases had 111 
some form of INH resistance. Of concern, the only high HIV burden country with data 112 
sufficient to analyse time trends (Botswana), had seen an increase in INH resistance. New 113 
data from the South African drug resistance survey of 2012-14 (which are presented 114 
nationally and by province) also indicate increasing prevalence.17 115 
 116 
 117 
5 
RESISTANCE MUTATIONS 118 
Phenotypic INH resistance is associated with a number of mutations;18 at the time of writing 119 
this review, 22 were documented by the TB Drug Resistance Mutation Database.19;20 120 
Determining the minimal number of mutations required to effectively detect INH resistance in 121 
a clinical setting is thus complex.21 Lack of clarity about the association between specific 122 
mutations, phenotypic resistance, and treatment outcomes hinders genotyping being used to 123 
make rapid treatment decisions.22;23 inhA mutations are generally associated with lower 124 
phenotypic resistance than katG mutations,24;25 but even within the same gene different 125 
mutations can cause differing levels of phenotypic resistance. For example, in vitro katG 126 
H270R mutations result in greater resistance levels than A162E, with the commonly studied 127 
S315T mutation between the two.25 Beyond the role of single point mutations, a strain’s 128 
genetic background contributes to the relationship between the genotype of resistance loci 129 
and phenotypic resistance,26 as does the presence of compensatory mutations e.g. in 130 
ahpC.27 It is important to note that inhA promoter mutations also affect susceptibility to 131 
ethionamide, a core second line agent.28 132 
 133 
The distribution of different INH resistance mutations has been less well mapped globally 134 
than general prevalence data, but estimates from an international collection of over 5,000 135 
strains (bearing in mind issues due to clustering and sampling) suggest that 79% of non-136 
MDR INH resistant isolates have the katG S315T mutation (Manson et al., currently under 137 
review). Information on the distribution of mutations in non-MDR INH resistant TB is also 138 
individually available from various settings e.g. China (49% of isolates found to have the 139 
katG S315T mutation),29 Ethiopia (60% katG),30 Switzerland (57% katG S315T),26 plus pan-140 
country studies e.g. Georghiou et al. (although this includes MDR strains).31 Given that some 141 
mutations are less strongly linked to high-level phenotypic resistance (and thus theoretically 142 
poor treatment outcomes with INH-containing regimens) than others, such data are critically 143 
important for global planning (Table 1). 144 
 145 
THE INFLUENCE OF RESISTANCE ON TREATMENT OUTCOMES 146 
A high burden of non-MDR INH resistance is concerning in terms of TB control if the relative 147 
and absolute likelihood of negative treatment outcomes is substantially higher for INH 148 
resistant versus drug sensitive disease. 149 
 150 
An early review of British Medical Research Council trials of different active TB treatment 151 
regimens published in 1986 was optimistic on this front, contrasting ‘the high success rate of 152 
short-course regimens in the presence of initial resistance to isoniazid and streptomycin’ to 153 
‘the response of the few patients with initial rifampicin resistance’ (some of whom were 154 
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MDR).32 Results differed in a more recent and expansive systematic review and meta-155 
regression of trial data.11 The authors found that, after controlling for the different 156 
components of treatment regimens, initial INH resistance increased incidence rates of 157 
treatment failure and relapse versus a baseline of pan-sensitive strains (incidence rate ratio 158 
10.9 [95% confidence interval 5.9-20] and 1.8 [1.2-2.6], respectively). Some observational 159 
studies from a variety of settings (with and without adjustment for treatment regimen and 160 
other confounders) have found similar results, including the previously cited study examining 161 
deaths in TB meningitis patients.10;33;34 Other studies have not found an association between 162 
resistance and negative outcomes.35;36 A large retrospective cohort of patients receiving 163 
short course chemotherapy from six countries was also less clear cut, showing an 164 
association between INH resistance and the risk of treatment failure in retreatment cases 165 
and weaker statistical evidence among new cases.37 166 
 167 
Different levels of phenotypic resistance might be expected to influence the success of INH-168 
containing regimen. Indeed, as stated by Van Deun et al. ‘[b]ecause of the large therapeutic 169 
range of isoniazid, a fraction of patients may still benefit from the drug because the high 170 
concentration achievable in tuberculosis lesions may overcome low-level resistance’.38 Many 171 
studies comparing treatment outcomes in individuals with high and low level phenotypic 172 
resistance have not reported differences, although analyses are frequently not adequately 173 
statistically adjusted and the methodology for determining resistance will also have been 174 
influential.22;34;39-41 Published data on the influence of genotype are conflicting. In Vietnam, 175 
an analysis without adjustment for treatment regimen suggested that katG but not inhA 176 
mutations were associated with unfavourable treatment outcomes, and both mutations with 177 
relapse in new patients.42 In an Indian cohort where patients were all prescribed the same 178 
regimen katG, but not inhA mutations, were associated with poor treatment outcomes in an 179 
unadjusted analysis (and certain inhA mutations were more associated with cure than 180 
others).43 Other analyses have indicated that there is no difference in treatment outcomes by 181 
mutation, although again are often not appropriately adjusted.30;41;44  182 
 183 
On balance, therefore, the precise link between INH resistance and treatment outcomes is 184 
unclear, with disagreements likely due to how well studies statistically adjusted for 185 
confounding. Resistance is likely to be detrimental at least for certain sites of disease and 186 
without adapted treatment regimens. Further work is required (Table 1). 187 
 188 
TAILORING TREATMENT REGIMENS IN THE PRESENCE OF RESISTANCE  189 
If INH resistant TB has a greater likelihood of negative treatment outcomes than drug 190 
sensitive disease, then specific effective regimens are required. Substituting for INH is 191 
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clearly not ideal, given its low cost and frequency of adverse events. Global guidance does, 192 
however, often reflect the need for adjusted regimens, albeit without a consensus on the 193 
best approach to take (Table 2). A common theme of guidelines is the recognition of 194 
knowledge gaps requiring further research (Table 1). 195 
 196 
In a recent systematic review and network meta-analysis by Stagg et al. of randomised 197 
controlled trials of different treatment regimens for non-MDR INH resistant TB, 59 studies 198 
were found for inclusion.45 A regimen category of RMP-containing regimens using fewer than 199 
three effective drugs at four months, in which RMP was protected by another effective drug 200 
at six months, and RMP was taken for six months, was used as the baseline for a network 201 
meta-analysis (this included the WHO population level recommendation [Table 1]). 202 
Extending the duration of RMP to more than six months and increasing the number of 203 
effective drugs at four months to three or more lowered the odds of unfavourable versus 204 
favourable outcomes in a fixed-effects model (odds ratio 0.31 [95% credibility interval 0.12-205 
0.81]). This was the only regimen category where the credibility interval did not cross the 206 
null, however, in a random-effects model all estimates did so. In both models, this regimen 207 
category (RMP containing, three or more effective drugs at four months, RMP protected by 208 
another effective drug at six months, RMP taken for more than six months) and two others 209 
(RMP containing, fewer than three effective drugs at four months, RMP taken for six months; 210 
RMP containing, fewer than three effective drugs at four months, RMP taken for more than 211 
six months) consistently ranked in the top three out of the 11 included, albeit with much 212 
uncertainty. 213 
 214 
Menzies et al. also reviewed randomised controlled trials for the treatment of INH 215 
monoresistant TB in a paper published in 2009,46 with the aim of assessing the effectiveness 216 
of the 2008 WHO ‘retreatment’ regimen (two months of STM INH RMP PZA EMB followed 217 
by one month of INH RMP PZA EMB and then five months of INH RMP EMB) in patients 218 
with INH resistant disease. Despite the two reviews having very different inclusion and 219 
exclusion criteria the findings were similar, with the Menzies et al. review concluding that a 220 
RMP duration of two months or less, having few drugs in the intensive phase, and therapy 221 
being delivered twice weekly throughout increased both treatment failure and relapse rates, 222 
with additional factors influencing one or other measure. It should be noted that, due to a 223 
lack of appropriate trials, Menzies et al. were unable to determine the efficacy/effectiveness 224 
of the specific WHO retreatment regimen for INH resistant TB. However, heterogeneous 225 
cohort study data indicated treatment failure in 18-44% of cases with INH resistance versus 226 
0.7-27% of patients with pan-sensitive strains. 227 
 228 
8 
High-quality data are lacking on the influence of treatment adherence, the use of 229 
combination pills, and the presence of different resistance mutations on the efficacy of 230 
regimen recommendations. Furthermore, people metabolise INH at different speeds 231 
depending upon their acetylator phenotype. This may also influence regimen efficacy, as fast 232 
acetylation can lead to less stable serum levels of INH, resulting in worse outcomes with INH 233 
containing regimens.47  234 
 235 
Additionally, neither of the two cited reviews specifically looked at regimens for children. For 236 
drug sensitive TB in children without HIV co-infection and in areas of a ‘low’ prevalence of 237 
INH resistance the WHO recommends a three-drug two-month intensive phase of INH, RMP 238 
and PZA, followed by four months of INH RMP.48 In the presence of INH resistance, or if the 239 
child is diagnosed where there is a ‘high background prevalence of isoniazid resistance’, 240 
WHO state that EMB should be added during the intensive phase and that ‘[f]or patients with 241 
more extensive disease, consideration should be given to the addition of a fluoroquinolone 242 
and to prolonging treatment to a minimum of 9 months’. Indeed, observational studies 243 
suggest that fluoroquinolones may play a role in treating both adult and childhood 244 
disease,39;49 at least where it is extensive (Table 1).  245 
 246 
FROM INH RESISTANCE TO MULTIDRUG RESISTANCE 247 
Aside from the implications of INH resistance on treatment, if non-MDR INH resistance is the 248 
key precursor to MDR (as opposed to non-MDR RMP resistance) and the risk of progression 249 
from INH resistance to MDR is high enough, then the control of such strains is very 250 
important. The relative prevalence of different resistance patterns across settings can be 251 
informative here, as can studies of the particular INH resistance mutations commonly 252 
observed in MDR strains. At a population level, evidence can also be provided through 253 
phylogenetic studies calculating the temporal order in which mutations occur. If we are 254 
convinced that INH resistance precedes RMP resistance then the risk/rate of a strain 255 
becoming MDR once INH resistant becomes critical. This is calculable through clinical trials 256 
and prospective observational studies analysed at the individual level. We examine each line 257 
of evidence in turn in the following paragraphs. 258 
 259 
Globally, the proportion of RMP resistant strains that are MDR is higher than the equivalent 260 
proportion of INH resistant strains. An analysis of aggregate WHO data from 125 settings 261 
and several years has estimated that 87% of RMP resistant isolates are MDR.50 By 262 
comparison, using available nationwide data from Jenkins et al.,12 we calculated an average 263 
(weighted by the population in each country) of 39% of INH resistant strains being MDR. (It 264 
should be noted that this estimate relies upon reported data that is two or more decades old 265 
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in some cases.) Such patterns likely reflect at least one of three things- the relatively high 266 
INH resistance mutation rate as opposed to that for RMP;51 that strains, once RMP resistant, 267 
rapidly acquire additional INH resistance; or that INH resistance is generally the first step to 268 
MDR.  269 
  270 
Given that katG mutations are generally associated with greater phenotypic resistance than 271 
inhA mutations, if INH resistance is the first step to MDR it might be assumed that the former 272 
will be more common in MDR strains than the latter. Studies in various settings (of which the 273 
cited are a few) have demonstrated this to be the case,26;29;30;52-58 (including enrichment of 274 
katG mutations in MDR versus non-MDR INH resistant strains21;26;29;30;59). The ‘spectrum’ of 275 
mutations observed in MDR strains varies from setting to setting, however, and may be 276 
linked to the dose of INH used for treatment57 and the clonal spread of different mutations.  277 
The prevalence of different mutations will also reflect relative fitness, which is a complex 278 
trait60 that may additionally be related to the speed at which bacteria are growing.61 279 
  280 
A systematic review and meta-regression of trial data published by Menzies et al. in 2009 281 
examined the question of whether initial INH resistance is associated with increased rates of 282 
additional resistance.11 Incidence rates of acquired drug resistance were found to increase 283 
5.1 times in patients with INH resistant disease versus drug sensitive disease (95% 284 
confidence interval 2.3 to 11.0) after treatment regimen was controlled for. This study 285 
examined any additional resistance to the drugs received, rather than looking specifically at 286 
the transition to MDR, however (Table 1). Although there are randomised controlled trials 287 
that specifically document RMP resistance arising in INH resistant versus drug sensitive 288 
patient populations by regimen both during and after treatment, data are relatively minimal.62-289 
74 Within these trials (all of which used RMP in all arms) the development of RMP resistance 290 
almost exclusively occurred in less than 1% of drug sensitive disease patients across failure 291 
and relapse. In most instances this was also true for INH resistant disease. Notable 292 
exceptions in the latter population (high risk of progression during treatment [8-31%], but not 293 
at relapse) occurred when regimens consisted of INH and RMP alone (plus minimal STM, or 294 
STM in the presence of STM co-resistance). One trial in HIV positive individuals documented 295 
a much higher risk of developing RMP resistance in drug sensitive patients during both 296 
treatment failure and relapse and INH resistant patients during treatment failure, but this may 297 
have been because patients were repeatedly re-infected during treatment.73 Although the 298 
findings above do not include trials where a comparator drug sensitive disease group was 299 
missing or where information was not presented by treatment regimen, it does given an 300 
indication of a generally low risk of the development of additional resistance. By comparison, 301 
observational studies without a comparator drug sensitive disease group have documented 302 
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highly differing estimates of the likelihood of INH resistant disease progressing to MDR, 303 
ranging from <1-10%.39;44;75-78 In both randomised controlled trials and observational studies, 304 
estimates will be highly regimen dependent. 305 
 306 
Rapid and cheap whole genome sequencing makes analysing the progressive gain of 307 
resistance mutations at the population level using phylogenetic trees an achievable 308 
approach.79 A recent study of samples from a particular Mycobacterium tuberculosis clone 309 
from KwaZulu-Natal in South Africa indicated that INH resistance (katG) mutations arose 310 
approximately 30 years earlier than RMP resistance.80 A previous study from Argentina also 311 
placed katG mutations prior to rpoB ones, albeit with a much shorter (3 year) gap and 312 
overlapping confidence intervals.81 Other studies using different typing techniques (including 313 
phenotyping) at the individual or population level have similarly suggested that INH 314 
resistance arises before RMP resistance.82-85 Results at the population level may, however, 315 
simply reflect when the different drugs were introduced and the more rapid mutation rate to 316 
INH resistance. A recent study across five continents, however, not only indicated that in 317 
96% of MDR strains INH resistance was observed before RMP resistance, but also that this 318 
was independent of lineage, where strains were sampled from, and the time when resistance 319 
arose i.e. INH resistance predated RMP resistance even after both drugs were in use 320 
(Manson et al., currently under review). 321 
 322 
Saunders et al. have proposed that INH resistance might precede RMP resistance in the 323 
development of MDR because the selective pressure of RMP is smaller than that of INH, 324 
thus RMP resistant strains are more likely to be killed by INH than INH resistant strains by 325 
RMP.84 The INH resistant strains thus survive and develop additional resistance during 326 
substandard treatment. A higher mutation rate in strains with katG mutations in the presence 327 
of oxidative stress has also been suggested as a potential explanation, although evidence is 328 
lacking.86 329 
 330 
HOW CAN WE PREVENT INH RESISTANCE? 331 
The prevention of INH resistance falls into two categories- the need to control the spread of 332 
INH resistant strains (primary resistance) and the need to prevent patients developing 333 
secondary resistance. 334 
 335 
The prevention of primary resistance relies upon ensuring that INH sensitivity is documented 336 
in all patients- preferably using rapid techniques- who are promptly placed on an effective 337 
treatment regimen. Importantly, modelling work has indicated no evidence that the katG 338 
S315T mutation (for example) impairs virulence or transmissibility.87 Effective treatment 339 
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regimens for INH resistant LTBI (which may need to be different to standard regimens) are 340 
also important, including knowing when the population level prevalence of resistance is 341 
sufficient to require such regimens to be used nationally as opposed to only in contacts of 342 
INH resistant disease cases.  343 
 344 
Guidance and studies on the treatment of drug resistant LTBI infections are few and far 345 
between, with work focussing on MDR. Early reports exist of INH prophylaxis failing in 346 
contacts of patients with INH resistant TB, but such studies do not contain good comparison 347 
estimates of the failure of prophylaxis in individuals with drug sensitive infections.88-90 Neither 348 
the WHO nor (for example) the National Institute for Health and Care Excellence, UK make 349 
explicit recommendations regarding the treatment of contacts exposed to INH resistant TB 350 
(including for children).9;48;91 The American Thoracic Society and Centers for Disease Control 351 
and Prevention, USA recommend a four month regimen of RMP for such individuals (six 352 
months for children),92-94 unless they are ‘HIV-infected persons taking some combinations of 353 
[antiretroviral therapy]’. This recommendation was based upon a small number of 354 
publications.89;95-98 Of note, three to four months of RMP is the only non-INH containing 355 
regimen currently recommended for LTBI by the WHO.9 In the absence of clearer evidence 356 
from trials and observational studies about whether INH-containing regimens are suitable for 357 
INH resistant LTBI (Table 1), data may also be gleaned by comparing the results of studies 358 
undertaken in settings of different INH resistance prevalences. 359 
 360 
In order to estimate the critical prevalence of INH resistance before RMP LTBI regimens 361 
should replace nine months of INH, a modelling study was undertaken in migrant children.99 362 
From a cost/benefit perspective, the regimen switch was recommended for children 363 
originating from settings where the prevalence is at least 11%. The study was, however, 364 
criticised by other researchers, particularly for its assumptions regarding the relative 365 
effectiveness of different LTBI regimens.100 366 
 367 
The prevention of secondary resistance largely relies upon ensuring appropriate adherence 368 
to treatment, responsive monitoring of patient progress, and ensuring good access to drugs 369 
to avoid regimen breaks.101 Higher strength pills (to reduce the number of tablets a patient 370 
takes at any one time) and combination pills may improve adherence and ensure adequate 371 
dosing. Regimens- particularly if they are intermittent- may need to be tailored to acetylation 372 
phenotype.102 Additionally, the role of INH preventative therapy in producing INH resistant 373 
LTBI has been debated.103;104 Of note, INH resistant disease in this instance would be 374 
incorrectly classified as having primary drug resistance. 375 
 376 
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CONCLUSION 377 
INH is an important drug for the control of TB that we cannot afford to lose. It is cheap, 378 
effective, has a low rate of adverse events, and cannot currently be substituted by an equal 379 
alternative. Non-MDR INH resistance is surprisingly prevalent globally, especially in former 380 
Soviet Union countries. Resistance may increase the likelihood of negative treatment 381 
outcomes, post-treatment relapse, and death at least for certain sites of disease and with 382 
specific regimens. The incidence of non-MDR INH resistance (which is higher than that of 383 
MDR-TB) may limit the effectiveness of INH preventative therapy at the population level.  384 
 385 
There are many knowledge gaps regarding INH resistant TB (Table 1). The most critical of 386 
these is perhaps the exact link between resistance-associated mutations, phenotypic 387 
resistance and active TB treatment outcomes. Rapid sequencing technologies make 388 
genotyping highly attractive as part of a pipeline to rapidly make patient-level treatment 389 
decisions, thus these links are crucial. Such technologies will, however, be hindered by the 390 
number of mutations associated with INH resistance. Better data on the burden of INH 391 
resistance globally is also required in order to ascertain whether INH preventative therapy 392 
policies should be adjusted. Importantly, none of the gaps highlighted would seem complex 393 
to fill. 394 
 395 
National interest in non-MDR INH resistance is context-specific, depending upon the extent 396 
to which a country is concerned about further resistance arising, the accessibility of first line 397 
drug sensitivity testing, the availability of alternative regimens for both LTBI and active 398 
disease, and budgetary limitations (including how much of a country’s resources are 399 
currently being spent on MDR). The WHO reflected this in their treatment guidelines- the 400 
recommendations of which are tailored to whether the local burden of resistance is deemed 401 
‘high’- stating ‘WHO does not intend to establish thresholds for low, moderate or high levels 402 
of prevalence of isoniazid resistance: [National Tuberculosis Programmes] will establish 403 
definitions for their own countries.’48  404 
 405 
Accurate drug sensitivity testing for all patients is critical for global TB control.1 As use of 406 
GeneXpert becomes more widespread, countries may cease testing for INH resistance, as 407 
samples negative for RMP resistance (used as a proxy for MDR) will undergo no further 408 
sensitivity testing. The implications of this are two-fold: even less data to estimate INH 409 
prevalence and a risk of inadequate treatment of non-MDR INH resistant disease, leading to 410 
further (undetected) transmission. This picture will change should GeneXpert XDR, which 411 
includes testing for at least some INH resistance genes, be trialled successfully.105 A 412 
modelling study using data from India has suggested a limited role for rapid INH resistance 413 
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testing on transmission, however.106 Comparatively, in Peru, GeneXpert in its current form is 414 
not favoured as a diagnostic due to the perceived importance of the country’s burden of INH 415 
resistant strains.107 416 
 417 
Readers may argue that non-MDR INH resistance has apparently been neglected for many 418 
years without too disastrous a consequence, and the fact that the proportion of non-MDR 419 
disease cases who fail treatment is low globally, despite the current prevalence of 420 
resistance, means that we need not be too concerned. This may well be the case in many 421 
settings and, indeed, we do not recommend that INH resistance be given priority over MDR 422 
and XDR-TB for research funding. Nevertheless, as a stepping stone to MDR, a high or 423 
increasing prevalence of INH resistance is concerning, and if tracked adequately in the past 424 
this may have aided the prevention of the MDR-TB epidemic. 425 
 426 
At the beginning of this article, we posed a question- to what extent is INH resistance a topic 427 
of concern? Our review of the literature suggests that non-MDR INH resistance has been 428 
neglected, and that this lack of focus needs to be addressed as an important means of 429 
controlling global TB. 430 
 431 
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TABLES 821 
Table 1: Summary of knowledge gaps for isoniazid resistant tuberculosis 822 
Area Missing information Potential data sources 
Prevalence of phenotypic INH 
resistance 
44% of the world’s 
population is not covered by 
prevalence data that could 
be included at the time of 
Jenkins et al.12 Many 
reported estimates are old. 
Temporal trend data are 
often missing. 
 
(Repeated) cross-
sectional studies, 
surveillance data 
Phenotypic versus genotypic 
resistance 
How do specific resistance-
associated mutations relate 
to phenotypic resistance? 
 
Cross-sectional 
microbiological studies 
Relative prevalence of 
resistance mutations 
How are the different INH 
resistance-causing mutations 
distributed globally? Does 
this differ within specific 
population groups e.g. 
populations deemed at high 
risk of MDR disease? 
 
Systematic review of 
available literature, 
cross-sectional studies 
Treatment outcomes in active 
disease 
How do phenotypic 
resistance (measured in 
different ways)22 and 
genotypic resistance 
influence treatment 
outcomes and the likelihood 
of relapse? 
 
Systematic review of 
available literature 
Treatment regimens for active 
disease* 
Are regimens with an 
increased dose of INH 
effective in instances of low-
level phenotypic resistance? 
What are the best regimens 
in children? At what 
resistance prevalence 
threshold should 
recommendations to use 
specific regimens be made? 
 
Randomised controlled 
trials, mathematical 
modelling, health 
economics 
Progression to MDR What is the absolute risk of 
INH resistant strains 
becoming MDR during 
treatment? How does this 
compare to drug sensitive 
disease? How does this 
relate to treatment regimen? 
 
 
 
 
 
Systematic review of 
available literature, 
cohort studies 
26 
LTBI treatment regimens How effective are currently 
recommended LTBI 
treatment regimens for INH 
resistant infection? Are other 
regimens required, including 
for children? At what 
population-level of INH 
resistance is it best to avoid 
INH preventative therapy? 
Randomised controlled 
trials, mathematical 
modelling, health 
economics 
*The American Thoracic Society,108 National Institute of Health and Care Excellence, UK91 823 
and World Health Organization5 all have their own recommendations on this topic. The 824 
American Thoracic Society has recently updated their guidance on the treatment of drug 825 
sensitive disease, but at the time of writing new guidelines for treating drug resistant disease 826 
have not been released. INH- isoniazid, LTBI- latent tuberculosis infection, MDR- multidrug 827 
resistance 828 
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Table 2: Global guidance on treating isoniazid resistant tuberculosis disease in adults 831 
Issuer of guidance Treatment regimen(s) recommended Reference(s) 
World Health 
Organization 
Two sets of guidance, one on the basis of 
background levels of INH resistance and non-
availability of drug sensitivity testing before the 
continuation phase of treatment, the other when 
individual-level drug sensitivity testing is available. 
Where background levels are deemed ‘high’ among 
new TB patients and INH susceptibility testing 
results are not available before the continuation 
phase two months of INH, RMP, PZA and EMB 
followed by four months of INH, RMP and EMB are 
recommended. The threshold for ‘high’ levels is not 
defined.48 
In the presence of individual-level drug 
susceptibility results, recommendations are made 
depending upon the non-MDR INH resistance 
pattern found. For example, six to nine months of 
RIF, PZA and EMB (plus or minus a 
fluoroquinolone) for INH-monoresistant or INH and 
STM-resistant disease. 
 
5;109 
American Thoracic 
Society 
Six month regimen of RMP, PZA and EMB (plus a 
fluoroquinolone for extensive disease). 
 
108 
National Institute of 
Health and Care 
Excellence, UK 
Nine month regimen (10 months where disease is 
extensive) of two months of RMP, PZA and EMB, 
then seven months of RMP and EMB. 
91 
EMB- ethambutol, INH- isoniazid, PZA- pyrazinamide, RMP- rifampicin, STM- streptomycin 832 
  833 
28 
FIGURE LEGENDS 834 
Figure 1: Percentage of incident tuberculosis cases with isoniazid resistance but not 835 
rifampicin resistance, 1994-2009 836 
World map showing the percentage of incident tuberculosis disease that was isoniazid 837 
resistant, but not multidrug resistant, 1994-2009. National level data only, sourced and 838 
analysed as per Jenkins et al.12 Where countries submitted repeated estimates most recent 839 
data shown only. White areas did not report national data during the time period in question.  840 
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FIGURES 842 
Figure 1: Percentage of incident tuberculosis cases with isoniazid resistance but not 843 
rifampicin resistance, 1994-2009 844 
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